“…In line with our results, a higher expression of SCRIB in human cancers has been reported in CRC [ 20 , 37 ], hepatocellular carcinoma [ 22 ], breast cancer [ 15 ], and prostate cancer [ 15 ]. Furthermore, a higher expression of SCRIB also predicted shorter survival of ovarian carcinoma [ 24 ] and gastric carcinoma [ 7 ]. However, controversially, the expression of SCRIB was decreased compared to normal tissue in oropharyngeal squamous cell carcinoma, breast cancer, uterine cervical cancer, lung cancer, and lymphoma [ 15 , 38 ].…”